Alfonso Quintás-Cardama
2023
In 2023, Alfonso Quintás-Cardama earned a total compensation of $1.8M as Chief Medical Officer at Foghorn Therapeutics.
Compensation breakdown
| Bonus | $110,000 |
|---|---|
| Non-Equity Incentive Plan | $43,400 |
| Option Awards | $1,544,374 |
| Salary | $144,432 |
| Other | $2,329 |
| Total | $1,844,535 |
Quintás-Cardama received $1.5M in option awards, accounting for 84% of the total pay in 2023.
Quintás-Cardama also received $110K in bonus, $43.4K in non-equity incentive plan, $144.4K in salary and $2.3K in other compensation.
Rankings
In 2023, Alfonso Quintás-Cardama's compensation ranked 587th out of 2,918 executives tracked by ExecPay. In other words, Quintás-Cardama earned more than 79.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 587 out of 2,918 | 80th |
Division Manufacturing | 334 out of 1,608 | 79th |
Major group Chemicals And Allied Products | 232 out of 901 | 74th |
Industry group Drugs | 229 out of 864 | 74th |
Industry Pharmaceutical Preparations | 144 out of 622 | 77th |
Source: SEC filing on May 3, 2024.
Quintás-Cardama's colleagues
We found two more compensation records of executives who worked with Alfonso Quintás-Cardama at Foghorn Therapeutics in 2023.